Retaane
(anecortave acetate)Phase 3Small molecule
Anecortave acetate is used to treat wet age-related macular degeneration, a condition that causes vision loss in older adults by damaging the central part of the retina at the back of the eye.[1] Retaane is currently being investigated across 14 indications[3], with its most advanced program in Phase 3.[1]
Retaane is one of 214 small molecule programs targeting Telangiectasis. It is currently in Phase 3.
14
Indications
30
Total Trials
0
Active Trials
213
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment6 trials
Age-Related Macular Degeneration5 trials
Open-Angle Glaucoma3 trials
Trial3 trials
9 more indications
Intraocular Pressure2 trials
Retinopathy2 trials
Retinal Vein Occlusion1 trial
Wet Age-Related Macular Degeneration1 trial
CLE1 trial
Diabetic Retinopathy1 trial
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anecortave acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAlcon Research